Cendakimab

僅用于工業(yè)應(yīng)用或科學(xué)研究，不可用于人類或動物的臨床診斷或治療，非藥用. Cendakimab （RPC4046; ABT 308; CC-93538） is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases （e.g., asthma and eosinophilic esophagitis）